Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [89Zr]rituximab.
Moccia M, De Stefano N and Barkhof F. Imaging outcome measures for progressive multiple sclerosis trials. Mult Scler 2017; 23: 1614–1626. DOI: 10.1177/1352458517729456. On pages 1614 and 1620 of this article, positron emission tomography was incorrectly spelled as position emission tomography. SAGE and the authors apologise for any confusion.